<i>In Vitro</i> Activity and Microbiological Efficacy of Gepotidacin from a Phase 2, Randomized, Multicenter, Dose-Ranging Study in Patients with Acute Bacterial Skin and Skin Structure Infections

Nicole E. Scangarella-Oman, Karen Ingraham, Courtney Tiffany, Lynn Tomsho, Stephanie F. Van Horn, David Mayhew, Caroline Perry, Theresa C. Ashton, Étienne Dumont, Jianzhong Huang,

Antimicrobial Agents and Chemotherapy · 2019 · 17 citations · 25 references

DOIFull text

Open access

Concepts

Abstract

(GyrA S84L, ParC S80Y, and ParE D422E) or to confer elevated MICs to novel bacterial topoisomerase inhibitors (GyrA D83N, both isolates; ParC V67A, one isolate). This first report of microbiological outcomes and responses of gepotidacin in patients with ABSSSIs supports further evaluation of gepotidacin as a novel first-in-class antibacterial agent. (This study has been registered at ClinicalTrials.gov under identifier NCT02045797.).

References

25